Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

Clinical trial NCT06896916 · RECRUITING

Trial details

NCT number: NCT06896916
Sponsor: AbbVie
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2025-08-07
Primary completion: 2036-03-01
Enrollment: 135

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.